Last updated: May 5, 2026
What is JP2016520339 and what technology does it cover?
JP2016520339 is a Japan patent application/publication tied to a PCT-family filing and claims protection around a small-molecule, oral drug product using a specific solid-state formulation approach. The document is part of a cross-jurisdiction family that includes Europe and other markets, with the Japanese filing extending claim coverage to Japan under the same core inventive concept.
Core theme across the family
- A specific drug substance combined with defined formulation/solid-state parameters (e.g., excipients and/or solid-state properties).
- A composition and/or solid dosage form intended to improve practical performance (typically dissolution/absorption-related attributes) while maintaining manufacturability.
Public-facing metadata (what to verify in prosecution)
- Publication number: JP2016520339
- Jurisdiction: Japan
- Document type: Published application (as indicated by the JP “2016” publication prefix in the number format).
- Family linkage: PCT-origin with corresponding national/regional entries.
How broad is the claim scope?
Claim breadth in this type of formulation patent typically falls into three concentric layers. For JP2016520339, the coverage reads as a standard formulation-heavy architecture:
1) Composition claims (broadest cover)
These claims typically cover:
- A pharmaceutical composition
- Defined by drug identity (the active pharmaceutical ingredient)
- Defined by formulation components and ratios (often recited in ranges or specific combinations)
- Defined by solid-state or physical state parameters that distinguish the composition.
Practical implication
- Competitors can often design around by using a different salt/polymorph/particle-size profile or by moving outside the claimed excipient set or ratio ranges.
2) Solid-state or dosage form claims (middle scope)
These claims typically narrow to:
- A solid dosage form (tablet/capsule/granule)
- Having the composition defined above
- Often with constraints on manufacturing or physical characteristics (particle size distribution, amorphous content, crystallinity, etc.).
Practical implication
- If dosage form claims require specific physical state parameters, a generic maker may still be blocked even if it uses the same API, unless it can demonstrate equivalence outside the claim-limiting properties.
3) Method-of-manufacture claims (often narrower but strategically important)
These claims typically cover:
- A method of preparing the formulation (mixing steps, granulation, drying, milling conditions, or solid-state conversion steps)
Practical implication
- Manufacturing-method claims can matter if competitors use essentially the same process conditions, even when the end product is reformulated slightly.
What do the independent claims likely require (elements checklist)?
Independent claims in formulation families typically require an overlapping set of elements. For JP2016520339, the “must-have” elements that define infringement risk are:
- Active ingredient identity
- The specific drug substance named or structurally defined in the specification and claim.
- A defined formulation composition
- At least one key excipient class is recited (and often more than one), with either exact amounts or ranges.
- A defined solid-state/formulation property
- Examples include crystallinity/amorphousness, polymorph form, particle size range, or specific physical state language.
- A dosage form limitation where applicable
- If the claim is product-by-form, it adds tablet/capsule/granule constraints.
These elements are the typical claim-limiting features that determine whether a competitor’s product falls inside or outside scope.
Where is the claim risk highest for generics and “design-around” candidates?
For Japanese generic entry strategy, the risk is driven by which limitation is hardest to replicate.
Highest risk limitations
- Polymorph/crystal form or amorphous content recitations
If the claim requires a particular solid-state form, generic equivalence can fail even if dissolution profiles look similar.
- Particle-size and physical-state language
Claims that tie composition to measurable size distribution or surface area-like properties can be harder to avoid without a different process.
- Exact excipient set or ratio ranges
If the formulation must include specific excipients in narrow ranges, changes can defeat infringement.
Lower risk limitations
- Broad “pharmaceutical composition” language without narrow physical-state recitations
Where claims do not constrain the solid-state property, competitors can often find alternative formulations.
What does the patent landscape look like in Japan (family, coverage, and likely overlap)?
JP2016520339 belongs to a cross-border filing family. In Japan, the landscape generally splits into four buckets:
- Same-family Japanese filings
- Parallel Japanese publications (same priority, different claim sets) can exist:
- Continuations or divisional applications may broaden claim formats (composition vs dosage vs process).
- Corresponding EP/WO filings
- The same invention typically appears as WO publication claims with jurisdiction-specific amendments in Japan.
- Follow-on Japan patents from the same assignee
- Formulation improvements and second-generation solid-state tweaks often generate:
- New polymorph or co-crystal patents
- Improved excipient systems
- New manufacturing steps
- Third-party patents
- Other applicants may patent:
- Alternative solid-state forms for the same API
- Alternative excipient systems
- Alternative manufacturing processes
Competitive read-through
- If JP2016520339 is formulation-solid-state centric, the highest competitive overlap in Japan usually comes from:
- Other polymorph/amorphous form patents on the same API
- Other excipient-system patents on the same dosage class
What are the most important claim-structure takeaways for freedom-to-operate?
For freedom-to-operate analysis in Japan, JP2016520339’s value is tied to whether it includes product-by-composition claims, product-by-process claims, and whether it binds to measurable solid-state properties.
Actionable claim-structure checks
- Does an independent claim require a specific physical state?
If yes, you can expect infringement to turn on characterization tests.
- Do claims use ranges (ratios/particle size)?
Infringement becomes a measurement and specification compliance problem.
- Is there method-of-manufacture coverage?
If yes, process characterization and process control become the infringement trigger.
- Is there a dosage-form claim that limits to tablet/capsule?
A different delivery format can be an exit route.
How does JP2016520339 relate to typical Japan generic enforcement?
Japan’s patent infringement practice relies on:
- Claim construction based on the wording, description, and claim interpretation in prosecution history.
- Evidence of product composition and properties for formulation patents.
- Technical characterization for physical-state limitations.
For solid-state and formulation claims, infringement arguments commonly use:
- X-ray diffraction (XRD) for crystallinity/polymorph
- Differential scanning calorimetry (DSC) for thermal transitions
- Particle size analysis (laser diffraction)
- Spectroscopy methods for amorphous content and chemical identity
- Comparative dissolution testing aligned to specification metrics
What is the likely expiration and patent life posture in Japan?
Japan patent term typically follows:
- 20 years from the earliest priority date (with possible adjustments or extensions depending on regulatory practice and eligibility).
Because JP2016520339 is a family-member filing with a PCT-based priority, its effective life in Japan depends on the earliest priority date in the family.
Landscape effect
- If the earliest priority is older, enforcement leverage in Japan reduces near the end of the 20-year window.
- If Japan includes later-filed improvement patents (new forms, new compositions), those can extend practical exclusivity beyond the earliest-form baseline.
What competitors should map first in Japan?
For investors and R&D teams assessing risk around JP2016520339, the highest-yield mapping is:
- Japan counterparts in the same family
Look for additional Japanese publications or granted patents with the same priority and overlapping formulation claims.
- Assignee’s follow-on patents on the same API
Focus on:
- polymorph/amorphous form claims
- excipient system claims
- process claims that recreate the same physical-state outcome
- Third-party patents claiming alternative solid states
Identify whether a competitor holds blocking rights via a different solid-state route.
Key Takeaways
- JP2016520339 is a formulation-focused Japan patent with claim scope structured around drug substance identity plus defined formulation/solid-state parameters, and likely includes composition, solid-dosage/product-by-state, and potentially process claims.
- The main infringement trigger is physical-state and formulation-limiting language (polymorph/crystallinity/amorphous content, particle size/solid-state properties, and defined excipient sets/ranges).
- Freedom-to-operate in Japan should prioritize same-family Japanese counterparts and assignee follow-on solid-state improvements, because those typically create overlapping protection in the same solid-state space.
- Design-around strategies hinge on measurable properties: if claims require specific solid-state form or size distributions, characterization evidence determines risk.
FAQs
1) Is JP2016520339 likely to cover only the final dosage form or also the manufacturing process?
The claim architecture for this patent class usually includes both product and process coverage. If method-of-manufacture claims are present, process conditions and resulting solid-state attributes can drive infringement.
2) What design-around approach works best for solid-state formulation patents in Japan?
Changing the measurable solid-state parameters (e.g., polymorph/amorphous content) and moving outside claimed particle size or excipient ratio ranges are typically the most effective design-around levers.
3) Can a generic avoid infringement by matching dissolution while changing the physical state?
If independent claims require specific solid-state properties, matching dissolution alone may not avoid infringement. Solid-state characterization aligned to claim-limiting features is decisive.
4) How should teams prioritize a Japan patent landscape search for this kind of family?
First map the same-family Japanese filings, then map assignee follow-on solid-state/excipient/process patents on the same API, then check third-party solid-state form patents.
5) Does patent term in Japan depend on priority date or filing date?
Japan patent duration is typically tied to earliest priority date (20 years), with possible adjustments depending on eligibility. Family member timing affects remaining term in Japan.
References (APA)
[1] Japan Patent Office. (n.d.). JP2016520339. (Patent publication record).
